SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Fractyl Health, Inc. (GUTS) News

Follow Fractyl Health, Inc. (GUTS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol GUTS Asset equity Sector Markets 90 days 12 Last 0.8314 Updated Oct 16, 2026, 11:07 AM UTC Open live news feed Open GUTS chart & news
M Fractyl Health Says REMAIN-1 Meets Six-Month Co-Primary Endpoint Fractyl Health said Revita showed a statistically significant reduction in weight regain versus sham (p=0.0023). The company plans a De Novo FDA submission for late Q4 2026 and expects 12-month data in Q1 2027. EQUITY | Oct 16, 2026, 11:07 AM UTC M Fractyl Health Says Revita Met Six-Month Co-Primary Endpoint Revita retained about 80% of GLP-1-induced weight loss versus 67% for sham at six months (p=0.0023), Fractyl Health reported. EQUITY | Oct 16, 2026, 11:03 AM UTC L Fractyl Health's Revita meets six-month co-primary endpoint in REMAIN-1 study The ongoing pivotal study reported a statistically significant reduction in weight regain after GLP-1 discontinuation. EQUITY | Oct 16, 2026, 11:00 AM UTC L GUTS: Revita aims to transform post-GLP-1 weight maintenance with pivotal data and U.S. launch targeted for 2028 Revita is positioned as a durable, outpatient solution for post-GLP-1 weight maintenance, with pivotal data and a regulatory filing expected soon. The commercial strategy targets top bariatric centers, leveraging existin NEWS | Sep 14, 2026, 10:58 PM UTC L GUTS: Revita shows promise for durable weight maintenance post-GLP-1, with pivotal data expected soon Revita, an endoscopic procedure for post-GLP-1 weight maintenance, is nearing pivotal data readout and regulatory filing, with strong early efficacy and safety results. The commercial strategy targets top bariatric cente NEWS | Sep 14, 2026, 10:37 PM UTC L Fractyl Health Received Notice of Delisting On September 10, 2026, Nasdaq notified the company that its securities are subject to delisting from the Nasdaq Global Market after it failed to regain compliance with the $1.00 minimum bid price requirement by September NEWS | Sep 11, 2026, 08:25 PM UTC L Fractyl Health to take part in September investor conferences Fractyl Health said Harith Rajagopalan, M.D., Ph.D., will participate in upcoming September investor conferences. EQUITY | Sep 09, 2026, 11:03 AM UTC L GUTS - Fractyl Health to Participate in Upcoming September Investor Conferences GUTS - Fractyl Health to Participate in Upcoming September Investor Conferences EQUITY | Sep 09, 2026, 11:00 AM UTC L GUTS: Revita targets the urgent post-GLP-1 weight maintenance gap with scalable, cost-effective therapy Post-GLP-1 weight regain is a major unmet need, with millions of patients lacking durable maintenance options. Revita, a one-time endoscopic procedure, shows strong efficacy and safety, with a large addressable market an EQUITY | Sep 01, 2026, 06:29 PM UTC L GUTS: Revita targets the urgent post-GLP-1 weight maintenance gap with a scalable, cost-effective solution A large unmet need exists for post-GLP-1 weight maintenance, with Revita positioned as a one-time, outpatient procedure supported by promising clinical data and a favorable safety profile. The commercial strategy targets EQUITY | Sep 01, 2026, 04:52 PM UTC L GUTS: Revita aims to transform post-GLP-1 weight maintenance with a scalable, high-margin procedure Revita targets the unmet need for post-GLP-1 weight maintenance with a one-time outpatient procedure, supported by strong clinical evidence and a favorable safety profile. The commercial strategy leverages existing cente EQUITY | Sep 01, 2026, 03:55 PM UTC L GUTS: Revita offers a scalable, cost-effective solution for post-GLP-1 weight maintenance with rapid path to profitability Revita addresses the unmet need for post-GLP-1 weight maintenance with a one-time outpatient procedure, supported by strong clinical evidence and a favorable safety profile. The commercial strategy leverages existing inf EQUITY | Sep 01, 2026, 03:15 PM UTC L GUTS stockholder alert: Robbins LLP cites Fractyl Health class action Robbins LLP is referenced in a GUTS stockholder alert regarding a class action involving Fractyl Health, Inc., but no lawsuit details or financial impact are provided in the feed. REGULATION | Aug 22, 2026, 12:43 AM UTC L Fractyl Health to host virtual commercial strategy day on Sept. 1, 2026 Fractyl Health said it will host a virtual Commercial Strategy Day on Tuesday, September 1, 2026, focused on the potential path to commercializing Revita for post-GLP-1 weight maintenance. EQUITY | Aug 20, 2026, 11:00 AM UTC L GUTS - Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026 GUTS - Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026 EARNINGS | Aug 03, 2026, 08:05 PM UTC